Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025194 · ClinicalTrials.gov registry record · Phase 1
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025194: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00025194 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025194, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether BMS-247550 is more effective with or without estramustine in treating prostate cancer. PURPOSE: This randomized phase I/II trial is studying the best dose of ixabepilone when given together with estramustine and to see how well giving ixabepilone together with estramustine works compared to ixabepilone alone in treating patients with progressive prostate cancer.
Interventions
- DRUG ixabepilone
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
What the finished NCT00025194 record still lists
NCT00025194 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which ixabepilone is the first listed.
NCT00025194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025194 about?
NCT00025194 is a clinical study titled "Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether BMS-247550 is more effective with or without estramustine in treating prostate cancer. PURPOSE: This randomized ...
What is the current status of trial NCT00025194?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00025194?
The interventions under investigation include: ixabepilone (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00025194?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia